-transparent.png){kind=logo}
The single-dose pharmacokinetics of lubeluzole were investigated in 2 single-blind, placebo-controlled, dose-escalation studies in healthy male subjects. In the first study, 6 subjects received an intravenous infusion of 2.5, 5, and 10 mg lubeluzole. In the second study, a 15 mg dose of lubeluzole was administered to 6 subjects, of whom 5 also received 20 mg and 2 also 25 mg lubeluzole. Following the infusion, plasma lubeluzole concentrations decayed biphasically, with a mean distribution half-life (t1/2alpha) of 30 to 65 minutes and a mean terminal half-life (t1/2beta) of 15 to 24 hours. The results of the 2 studies indicate that lubeluzole exhibits linear kinetics over the dose range tested in healthy male subjects.
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
November 1997,
International journal of clinical pharmacology and therapeutics,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
March 2015,
Xenobiotica; the fate of foreign compounds in biological systems,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
August 1991,
British journal of clinical pharmacology,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
December 2016,
Xenobiotica; the fate of foreign compounds in biological systems,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
December 1981,
The Journal of antimicrobial chemotherapy,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
November 2012,
Xenobiotica; the fate of foreign compounds in biological systems,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
May 2018,
International journal of antimicrobial agents,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
January 1999,
Drugs in R&D,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
January 2005,
Antimicrobial agents and chemotherapy,
V Van de Velde, and
R Crabbe, and
A Van Peer, and
R Woestenborghs, and
N Van Osselaer, and
L Hantson, and
J Heykants
December 2000,
European journal of clinical pharmacology,
